Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed’s cloud-connected ventilators and proprietary software generate reams of regulatory data, making its disclosures dense even for seasoned analysts. If you have ever sifted through a 300-page report looking for AirSense sales or FDA recall language, you know the challenge. Stock Titan surfaces what matters in seconds, turning complicated respiratory-device statements into clear talking points.
Our AI reads every ResMed annual report 10-K simplified, scans each ResMed quarterly earnings report 10-Q filing, and flags fresh ResMed 8-K material events explained the moment they hit EDGAR. Want management sentiment? Real-time alerts track ResMed insider trading Form 4 transactions and the companion ResMed executive stock transactions Form 4 data stream. Policy votes and pay packages are covered in the ResMed proxy statement executive compensation section. All documents sit one click away, while concise paragraphs answer most popular searches such as understanding ResMed SEC documents with AI or “How do I find the latest ResMed Form 4 insider transactions real-time?”
Use these insights to:
- Compare PAP device revenue across quarters with AI-generated charts
- Spot insider buying ahead of new mask launches using our ResMed earnings report filing analysis
- Monitor product-recall language or patent disputes the minute they appear in an 8-K
ResMed Inc. (RMD) – Form 4 insider transaction: Director and Chairman emeritus Peter C. Farrell disclosed the sale of 945 common shares on 07/02/2025 at an average price of $255.49 per share. The trade, executed under a previously adopted Rule 10b5-1 trading plan dated May 28 2024, reduced Farrell’s direct holdings to 68,273 shares. No derivative securities were involved, and no additional transactions were reported.
The disposition represents roughly 1.4% of the insider’s pre-transaction stake and does not change his board status. Because the sale was pre-planned, it typically signals liquidity management rather than an active valuation call.
Form 4 Overview – ResMed Inc. (RMD)
Chief Financial Officer Brett Sandercock reported a series of option exercises and an open-market sale on 1 July 2025 under a pre-arranged Rule 10b5-1 trading plan dated 19 Feb 2025.
- Options exercised: 2,883 options (strike $101.64) converted into common shares. These options were granted 11 Nov 2019 and expire 14 Nov 2025.
- Shares sold: 3,883 common shares disposed at an average price of $256.99, generating gross proceeds of roughly $1.0 million.
- Net ownership change: Holding declined from 87,249 to 84,283 shares, a reduction of 2,966 shares (≈3.4% of his previously reported direct stake).
- Remaining equity exposure: Sandercock still owns 84,283 common shares and 8,000 vested, unexercised options, maintaining significant alignment with shareholders.
The transaction appears routine—driven by option maturity and executed under a 10b5-1 plan—but the net sale may be interpreted as mildly bearish sentiment or personal liquidity management. The limited magnitude relative to total holdings lessens market impact, yet investors often track C-suite sales as potential leading indicators.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
